hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06367868, orgStudyIdInfo id: E-83045809-604.01.02-179951, briefTitle: Optic Nerve Sheath Diameter: A Non-Invasive Indicator of Intracranial Pressure in the Intensive Care Unit Monitoring, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-09-09, primaryCompletionDateStruct date: 2022-06-01, completionDateStruct date: 2022-12-01, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Istanbul University - Cerrahpasa (IUC), class: OTHER, descriptionModule briefSummary: Determination of high intracranial pressure (ICP) is necessary for the treatment of patients with raised ICP to improve long-term neurological outcomes. Ultrasonographic optic nerve sheath diameter (ONSD) measurement is a noninvasive, easily performed and cost effective technique for detecting high ICP., conditionsModule conditions: ICP (Intracranial Pressure) Increase, conditions: Optic Nerve Sheath Diameter, conditions: Intracranial Hypertension, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 44, type: ACTUAL, armsInterventionsModule interventions name: After 5 ml CSF Drainage, outcomesModule primaryOutcomes measure: Intracranial Pressure-1 (ICP-1), primaryOutcomes measure: Optic Nerve Sheath Diameter-1 (ONSD-1), secondaryOutcomes measure: Intracranial Pressure-2 (ICP-2), secondaryOutcomes measure: Optic Nerve Sheath Diameter-2 (ONSD-2), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Istanbul University-Cerrahpasa, city: Istanbul, state: Fatıh, zip: 34098, country: Turkey, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06367855, orgStudyIdInfo id: KSKC20222025, briefTitle: Efficacy and Safety of Preemptive Intravenous Dexamethasone in MIS-TLIF : Double Blinded, Randomized Control Trial, acronym: MIS-TLIF, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-04-30, completionDateStruct date: 2025-05-31, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Potsawat Surabotsopon, class: OTHER, descriptionModule briefSummary: Researchers are considering Dexamethasone as preemptive medication before minimally invasive spine fusion surgery to minimize postoperative back pain with minimal side effects, aiming to enhance the effectiveness of surgery and improve patient outcomes., conditionsModule conditions: Spinal Stenosis Lumbar, conditions: Disc Degeneration, conditions: Disc Disease, conditions: Fusion of Spine, conditions: Surgery, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Dexamethasone, interventions name: Normal saline, outcomesModule primaryOutcomes measure: effectiveness of dexamethasone, secondaryOutcomes measure: Morphine consumption, secondaryOutcomes measure: Complication, secondaryOutcomes measure: Fusion rate, secondaryOutcomes measure: Length of hospital stay, eligibilityModule sex: ALL, minimumAge: 50 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06367829, orgStudyIdInfo id: WO.24.025, briefTitle: Lubinus SPII Hip Stem Target Trial Emulation (LARGE), acronym: LARGE, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-01-08, primaryCompletionDateStruct date: 2024-07-14, completionDateStruct date: 2025-01-08, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: JointResearch, class: OTHER, collaborators name: OLVG, collaborators name: Uppsala University, collaborators name: Göteborg University, collaborators name: Leiden University Medical Center, descriptionModule briefSummary: The research questions this study aims to answer are as follows:Primary research question:"Do primary total hip arthroplasties for patients with OA, hip fracture or osteonecrosis with the 150mm Lubinus SPII hip stem have better mortality and stem revision rates than primary total hip arthroplasties with the 130mm hip stem?"Secondary aims include:* How does line-to-line cementation, compare to undersized cementation in primary total hip arthroplasty for patients with OA, hip fracture, or osteonecrosis when comparing equal size Lubinus SPII hip stems implanted with different cementation techniques?* Does the Lubinus SPII 150mm hip stem perform equal to the Lubinus SPII 130mm hip stem in primary total hip arthroplasties for patients with OA, hip fracture or osteonecrosis when comparing patient reported outcome measures?To answer these questions, this study has been allowed use of registered data from the LROI (dutch arthroplasty registry) and the SAR (swedish arthroplasty registry). After exclusion of patients who did not meet inclusion criteria between 2007-2020, approximately 110000 patients remain eligible for analysis., conditionsModule conditions: Treatment Outcome, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: OTHER, enrollmentInfo count: 110000, type: ESTIMATED, armsInterventionsModule interventions name: Lubinus SPII hip stem 130mm, interventions name: Lubinus SPII hip stem 150mm, outcomesModule primaryOutcomes measure: Mortality rate, primaryOutcomes measure: Revision rate, secondaryOutcomes measure: NRS pain score, secondaryOutcomes measure: Oxford hip score, secondaryOutcomes measure: EQ - 5D, secondaryOutcomes measure: HOOS - PS, secondaryOutcomes measure: Revision rate, secondaryOutcomes measure: Mortality rate, eligibilityModule sex: ALL, minimumAge: 5 Years, maximumAge: 105 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: OLVG, city: Amsterdam, state: Noord Holland, zip: 1090 HM, country: Netherlands, geoPoint lat: 52.37403, lon: 4.88969, hasResults: False
protocolSection identificationModule nctId: NCT06367803, orgStudyIdInfo id: DVS010, briefTitle: Cost Analysis of Vascular Surgical Techniques, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-06-01, primaryCompletionDateStruct date: 2023-12-01, completionDateStruct date: 2024-03-01, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: University Hospital of Limerick, class: OTHER, descriptionModule briefSummary: Whilst mortality rates and surgical limitations are widely known and understood for each intervention performed, the cost implications, in UHL, are not known. Therefore, it is deemed a matter of interest to understand these costs and weigh them against the mortality rates for each intervention if available., conditionsModule conditions: Critical Limb Ischemia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 200, type: ACTUAL, outcomesModule primaryOutcomes measure: A comparative assessment of the cost implications of the surgical modalities used in the treatment of CLTI i.e., revascularisation and amputation., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University Hospital Limerick, city: Limerick, state: Munster, country: Ireland, geoPoint lat: 52.66472, lon: -8.62306, hasResults: False
protocolSection identificationModule nctId: NCT06367790, orgStudyIdInfo id: Bask-Pliomet, briefTitle: Plyometry and Tapping in the Functional Improvement of Non-professional Basketball Players, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2024-06-10, completionDateStruct date: 2024-07-01, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Universidad Católica San Antonio de Murcia, class: OTHER, descriptionModule briefSummary: Introduction. In basketball, the lower extremities have the highest prevalence of injury, regardless of gender and professional category.Objective. To analyse the efficacy of a physiotherapy intervention using a protocol of plyometric exercises and dry needling in non-professional basketball athletes.Methods. Randomised clinical study. 20 players will be randomised to an experimental group (plyometric exercises and dry needling of the gastrocnemius muscles) and a control group (plyometric exercises). The intervention will include 8 sessions over 4 weeks. The study variables will be: range of motion in dorsal flexion in loading (Leg Motion®) and unloading (goniometer) and vertical jump (MyJump2®).Expected results. An intervention of plyometric exercises and dry needling produces significant differences in range of motion and vertical jump in basketball players, compared to the isolated administration of plyometric exercises., conditionsModule conditions: Basketball Players, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Experimental group, interventions name: Control group, outcomesModule primaryOutcomes measure: Change from baseline range of motion in loaded dorsal flexion after treatment and at 4 weeks, secondaryOutcomes measure: Change from baseline range of motion in unloaded dorsal flexion after treatment and at 4 weeks, secondaryOutcomes measure: Change from baseline vertical jump after treatment and at 4 weeks, eligibilityModule sex: MALE, minimumAge: 18 Years, maximumAge: 30 Years, stdAges: ADULT, contactsLocationsModule locations facility: Rubén Cuesta-Barriuso, city: Oviedo, state: Asturias, zip: 33006, country: Spain, contacts name: Rubén Cuesta-Barriuso, PhD, role: CONTACT, phone: 607547274, email: cuestaruben@uniovi.es, geoPoint lat: 43.36029, lon: -5.84476, hasResults: False
protocolSection identificationModule nctId: NCT06367777, orgStudyIdInfo id: 2024/14MAR/132, briefTitle: Cervical/Thoracic Neuromodulation and Nociceptive Processing, acronym: MICROVOLT2, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2024-10, completionDateStruct date: 2024-10, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Université Catholique de Louvain, class: OTHER, descriptionModule briefSummary: Several studies have demonstrated that direct currents delivered through the skin at the level of the low-thoracic spinal cord can influence spinal cord function. In human volunteers, anodal low-thoracic transcutaneous spinal direct current stimulation (tsDCS) alters spinal processing of nociceptive inputs. Whether cervical tsDCS is able to do the same is less well known. In this double-blinded, sham-controlled and cross-over trial, the investigators will compare the effects on the nociceptive processing of healthy volunteers of cervical and low-thoracic tsDCS., conditionsModule conditions: Nociceptive Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 24, type: ESTIMATED, armsInterventionsModule interventions name: cervical a-tsDCS, interventions name: thoracic a-tsDCS, interventions name: sham tsDCS, outcomesModule primaryOutcomes measure: Change in contact-heat evoked potentials amplitude, secondaryOutcomes measure: Change in intensity of perception to contact-heat nociceptive stimuli, secondaryOutcomes measure: Change in skin temperature, secondaryOutcomes measure: Change in cutaneous blood flow, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 40 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06367738, orgStudyIdInfo id: 2024-11-14799, briefTitle: Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2025-04-01, primaryCompletionDateStruct date: 2026-12-30, completionDateStruct date: 2027-12-30, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: University of California, Berkeley, class: OTHER, descriptionModule briefSummary: We will use cognitive exams, perceptual tasks, brain imaging, peripheral psychophysiology, and surveys to investigate the persisting effects of psilocybin on cognition, predictive coding, and affect in healthy older adults. We will measure changes in these measures by comparing baseline to one-week and one-month post-treatment. Participants will be randomly assigned to receive a dose of psilocybin in a range from microdose to moderate-to-high dose. Dose response will be assessed. Anatomical magnetic resonance imaging (MRI) and diffusion weighted imaging (DWI) will be used to assess changes in brain structure, while functional magnetic resonance imaging (fMRI) will be used to quantify changes in functional brain activity. We will assess whether changes in these brain measures underlie observed changes in cognition, predictive coding and affect., conditionsModule conditions: Aging, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Psilocybin, outcomesModule primaryOutcomes measure: MRI measurements of brain structure, secondaryOutcomes measure: Amplitude and pattern of fMRI cortical responses, secondaryOutcomes measure: Peripheral psychophysiology, secondaryOutcomes measure: Perceptual measurements, secondaryOutcomes measure: Cognitive measurements, eligibilityModule sex: ALL, minimumAge: 60 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06367712, orgStudyIdInfo id: Ahmed Kassab, briefTitle: Letrozole Alone Protocol Versus Using Letrozole and HCG Protocol, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-11-10, primaryCompletionDateStruct date: 2023-11-01, completionDateStruct date: 2023-11-10, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Egymedicalpedia, class: INDUSTRY, descriptionModule briefSummary: Letrozole is a chemical compound, CGS 20267 which is a third-generation, nonsteroidal aromatase inhibitor.Letrozole blocks estrogen synthesis by directly affecting the hypothalamic-pituitary-ovarian axis, subsequently, increases gonadotropins which increase pregnancy rates. Possible positive outcomes of aromatase inhibitors over selective estrogen-receptor modulators include a more physiologic hormonal stimulation of the endometrium which increases receptivity, a lower multiple-pregnancy through single follicle growth, a lesser side-effect especially vasomotor and mood symptoms, and more prompt clearance from blood, hence, reducing the probabilities of periconceptional exposure, conditionsModule conditions: PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 132, type: ACTUAL, armsInterventionsModule interventions name: Letrozole tablets, outcomesModule primaryOutcomes measure: Pregnancy test, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 35 Years, stdAges: ADULT, contactsLocationsModule locations facility: Ahmed Maher Teaching Hospital, city: Cairo, country: Egypt, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06367699, orgStudyIdInfo id: H-44821, briefTitle: Conversational Agents to Improve HPV Vaccine Acceptance in Primary Care (ECA-HPV) Clinical Trial, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2027-09, completionDateStruct date: 2027-12, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Tufts Medical Center, class: OTHER, collaborators name: Boston Medical Center, collaborators name: Northeastern University, descriptionModule briefSummary: The objective of this study is to assess the use of and satisfaction with the ECA-HPV intervention over a 16-month period, its ability to increase HPV vaccination, and the comparative effectiveness of clinic notification and adolescent ECA components on these factors., conditionsModule conditions: Human Papilloma Virus, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 1750, type: ESTIMATED, armsInterventionsModule interventions name: Usual Care, interventions name: ECA-HPV App with Clinic Notification and Adolescent Functions Disabled, interventions name: ECA-HPV App with Clinic Notification Function Enabled, interventions name: ECA-HPV App with Adolescent Function Enabled, interventions name: ECA-HPV App with Clinic Notification and Adolescent Functions Enabled, outcomesModule primaryOutcomes measure: HPV vaccination series completion comparing the control group to the intervention groups, primaryOutcomes measure: HPV vaccination series completion comparing the intervention groups, secondaryOutcomes measure: HPV Knowledge, secondaryOutcomes measure: HPV Attitudes, secondaryOutcomes measure: General Vaccine Attitudes, secondaryOutcomes measure: ECA-HPV App Satisfaction, secondaryOutcomes measure: Clinic Notification Feature Satisfaction, eligibilityModule sex: ALL, minimumAge: 9 Years, maximumAge: 12 Years, stdAges: CHILD, contactsLocationsModule locations facility: Boston Medical Center, city: Boston, state: Massachusetts, zip: 02118, country: United States, contacts name: Lori Henault, MPH, role: CONTACT, phone: 617-414-6935, email: lori.henault@bmc.org, contacts name: Rebecca Perkins, MD, MSc, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 42.35843, lon: -71.05977, hasResults: False
protocolSection identificationModule nctId: NCT06367673, orgStudyIdInfo id: QH-ZYDC-01, briefTitle: Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-30, primaryCompletionDateStruct date: 2026-03-31, completionDateStruct date: 2026-08-31, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Zhejiang University, class: OTHER, collaborators name: Hangzhou Qihanjiyin Biotech Co.,Ltd., descriptionModule briefSummary: This is a phase 1, first-in-human (FIH), open-label, multicohort study to evaluate the safety, tolerability and preliminary efficacy of CLL1 or CD33 target Chimeric antigen receptor (CAR) -induced pluripotent stem cells derived NK cells in patients with relapsed/refractory AML, conditionsModule conditions: AML, Adult, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 24, type: ESTIMATED, armsInterventionsModule interventions name: iPSC-NK cells, outcomesModule primaryOutcomes measure: Incidence of Treatment-Emergent Adverse Events, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: the First Affiliated Hospital, School of Medicine, Zhejiang University, status: RECRUITING, city: Hangzhou, state: Zhejiang, zip: 321000, country: China, contacts name: Yongxian Hu, role: CONTACT, email: huyongxian2000@aliyun.com, geoPoint lat: 30.29365, lon: 120.16142, hasResults: False
protocolSection identificationModule nctId: NCT06367660, orgStudyIdInfo id: 98-2024, briefTitle: Comparison Between Hyperbaric Bupivacaine With Fentanyl vs. Hyperbaric Bupivacaine With Dexmedetomidine in Reducing Visceral Pain During Cesarean Delivery Under Spinal Anaesthesia, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-08, completionDateStruct date: 2024-09, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Tribhuvan University Teaching Hospital, Institute Of Medicine., class: OTHER, descriptionModule briefSummary: In patients undergoing elective LSCS under subarachnoid block, group BF will receive 0.5% hyperbaric bupivacaine 10mg (2ml) with fentanyl 10 mcg (0.2ml) with total of 2.2 ml and group BD will receive 0.5% hyperbaric bupivacaine 10 mg with Dexmedetomidine 5mcg (0.2ml) total volume 2.2ml. Assessment of intraoperative visceral pain will be done by self-reporting of patients, who are previously educated, as poorly localized discomfort or dragging, pulling heaviness or unpleasant feeling or pain with or without nausea and will be categorized according to preformed scale, conditionsModule conditions: Visceral Pain, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: SEQUENTIAL, interventionModelDescription: Research method: Quantitative Type of study: Randomized, interventional, comparative study, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 168, type: ESTIMATED, armsInterventionsModule interventions name: Intrathecal Bupivacaine-Fentanyl and Bupivacaine-Dexmedetomidine, outcomesModule primaryOutcomes measure: Primary outcome, secondaryOutcomes measure: Secondary Outcome, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False